One for all
6 October 2016
Email
Share
Half Alnylam’s market value evaporated after patient deaths ended a drug trial. The promise of novel treatments based on RNA interference had pushed its market value to $12 bln. That’s now down to $3 bln, suggesting investors fear trouble with one may indicate problems with all.
This content is for Subscribers only
To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.